Novel hormonal agents for metastatic Castration-Resistant Prostate Cancer: comparing outcomes. A single-center retrospective study

Prostate cancer is the most common cancer in men, accounting for 15% of all diagnosed cancers and is the sixth leading cause of cancerrelated deaths amongst men worldwide. Abiraterone and enzalutamide were the first two novel hormonal agents approved for the treatment of metastatic prostate cancer b...

Full description

Bibliographic Details
Main Author: Jarimba, Roberto Saldanha (author)
Other Authors: Eliseu, Miguel Nobre (author), Pedroso Lima, João (author), Quaresma, Vasco (author), Moreira, Pedro (author), Nunes, Pedro Coelho (author), Silva, Edgar Tavares da (author), Figueiredo, Arnaldo José (author)
Format: article
Language:eng
Published: 2021
Subjects:
Prostate cancer
Abiraterone
Enzalutamide
Castration-resistant
Abiraterone Acetate
Humans
Male
Prospective Studies
Retrospective Studies
Treatment Outcome
Antineoplastic Agents
Prostatic Neoplasms, Castration-Resistant
Online Access:http://hdl.handle.net/10316/100893
Country:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/100893

Internet

http://hdl.handle.net/10316/100893

Similar Items